2017 IPO

Quanterix Stock

Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.

Sign up today and learn more about Quanterix Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Quanterix Stock

Quanterix Corporation is developing a novel platform for single molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. Founded in 2007, Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.

Funding History

August 2008$15.0M
October 2010$2.5M
August 2011$6.0M
March 2012$2.0M
November 2012$18.5M
March 2016$46.0M


Chief Medical Officer

Andreas Jeromin

Senior Director, Manufacturing Operations

James Drummey

Senior Director, Sales & Marketing

Julien Bradley

VP, Product Development

David H. Wilson

Scientific Founder & Board Director

David R. Walt

Chairman & CEO

Kevin Hrusovsky

CTO & VP, Research

David Duffy, Ph.D.


Ernest Orticerio


Paul M. Meister

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: